SynthesisFrontiers in immunology2023
Dupilumab for the treatment of prurigo nodularis: A systematic review.
Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross-Sectional Population-Based Analysis.International journal of dermatology · 2026Article
- IL-13 and skin fibrosis in inflammatory skin diseases.Frontiers in immunology · 2026Review
- Severe non-atopic prurigo nodularis in an otherwise healthy elderly patient: rapid multidimensional response to dupilumab.Frontiers in pharmacology · 2026Article
- A Rare Case of Dupilumab Monotherapy in Pemphigoid Nodularis and a Comprehensive Literature Review.Cureus · 2025Article
- Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy.Acta dermato-venereologica · 2025Article
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Dupilumab-Induced Generalized Lichen Planus: A Case Report.Journal of inflammation research · 2025Article
- Dupilumab-Induced Systemic Hypoperfusion in an Elderly Patient: A Case Report.Journal of inflammation research · 2025Article
- Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect.JAAD case reports · 2024Article
- Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.The Journal of clinical psychiatry · 2024Review
- Case report: Dupilumab-induced linear psoriasis: a rare presentation.Frontiers in medicine · 2024Article
- Potential Indications of Dupilumab in Th-2 Inflammatory Disease.Reviews on recent clinical trials · 2024Review
- Assessing the use of dupilumab in a pediatric patient with bullous congenital ichthyosiform erythroderma.JAAD case reports · 2023Article
- Skin Microbiome in Prurigo Nodularis.International journal of molecular sciences · 2023Article
- Use of dupilumab in the management of refractory prurigo nodularis in an immunosuppressed double transplanted patient.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab. Objective: The objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis. Methods: Several databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study. Results: After 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119). Conclusions: Dupilumab has definite effectiveness and safety in prurigo nodularis treatment. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.